Squamous Cell Carcinoma.Care & specialists in Sri Lanka

SCC is the second most common skin cancer, arising from epidermal keratinocytes after cumulative UV damage. It appears as a scaly, often tender nodule or non-healing sore on sun-exposed skin. Unlike BCC, SCC can spread to lymph nodes and distant organs in 3-15% of high-risk cases.

Most cSCCs are curable when treated early — 5-year cure exceeds 95% for low-risk lesions. High-risk SCC has 5-15% metastatic risk. Patients with nodal involvement have 5-year survival of 25-40%. Cemiplimab transformed care for advanced disease.

Cutaneous SCC appears as a rough, scaly, hyperkeratotic, often tender nodule or plaque on sun-exposed skin. Some ulcerate with central crust; others form a dome-shaped nodule with a keratin crater (keratoacanthoma variant). Bowen disease appears as a red scaly patch.

Yes. Cutaneous SCC has substantial metastatic potential — 3-5% in typical cases, rising to 25-50% in high-risk subgroups (lip, ear, perineural, immunosuppression). Regional lymph nodes are most common, followed by lungs, bone, brain, and liver. Early treatment reduces this risk.

Treatment depends on risk. Mohs micrographic surgery is preferred for high-risk SCC with 5-year cure rates of 97%. Standard excision with 4-6 mm margins cures 92-95% of low-risk lesions. Cemiplimab is used for locally advanced or metastatic disease, with response rates of 47%.

Cutaneous SCC typically grows faster than BCC — visible enlargement over weeks to months. Keratoacanthoma variants can double in size within a few weeks. Sudden rapid growth signals aggressive disease and warrants urgent biopsy. Bowen disease (SCC in situ) grows slowly.

Cumulative UV radiation is the dominant cause, producing UV-signature mutations in TP53 and other genes. Other causes include tanning, immunosuppression, high-risk HPV, chronic wounds (Marjolin ulcer), arsenic, prior radiation, and genetic syndromes like xeroderma pigmentosum.

Mohs micrographic surgery removes the tumor in stages while examining 100% of each margin under the microscope. Preferred for high-risk SCC on face, head, neck, ear, and lip. It achieves 5-year cure rates of 97% for primary and 92% for recurrent SCC — the highest of any modality.

Yes. Local recurrence occurs in 5-25% of cases depending on tumor risk and treatment. Second-primary cSCC develops in 30-50% of patients within 5 years. Lifelong dermatology surveillance and strict photoprotection are standard. Most recurrences are caught at routine follow-up.

Cemiplimab is an anti-PD-1 monoclonal antibody given as 350 mg IV every 3 weeks. It was the first systemic therapy FDA-approved for advanced cSCC, with response rates of 47% in EMPOWER-CSCC-1. Median response exceeds 24 months. Immune-related side effects can occur.

BCC arises from basal keratinocytes, grows slowly, and rarely metastasizes (under 0.1%). SCC arises from full-thickness epidermal keratinocytes, grows faster, and can metastasize in 3-15% of high-risk cases. BCC looks pearly with rolled borders; SCC is scaly and often tender.

Bowen disease is SCC in situ — full-thickness epidermal dysplasia without basement-membrane invasion. It appears as a red scaly patch resembling eczema. Progression to invasive SCC occurs in 3-5% of lesions. Treatment options include 5-FU, imiquimod, cryotherapy, PDT, or excision.

Yes — solid organ transplant recipients develop cSCC at 60-100 times the rate of the general population, often with multiple aggressive tumors. Risk rises with cumulative immunosuppression. They need dermatology surveillance every 3-6 months plus chemoprevention.

Mortality from typical low-risk cSCC is under 1%. High-risk SCC with metastasis has 5-year survival of 25-40%; distant disease historically 10-20%, though cemiplimab now achieves durable responses in half of treated patients. Annually 5,000-15,000 US patients die of cSCC.

Marjolin ulcer is SCC arising in chronic scars, burn wounds, sinus tracts of osteomyelitis, or long-standing ulcers. It develops 10-30 years after the original injury and carries 25-30% metastatic risk — much higher than typical cSCC. Any non-healing scar wound warrants biopsy.

Yes — most cSCCs are preventable through strict photoprotection. Apply SPF 30+ daily, wear UPF 50 clothing and hats, avoid peak UV hours, never use tanning beds. Treat actinic keratoses promptly. Nicotinamide 500 mg twice daily reduces new NMSC by 23% per ONTRAC trial.

Staging uses AJCC 8th edition TNM and the Brigham and Women's Hospital classification. Key factors include diameter (over 2 cm), depth (over 6 mm or beyond fat), perineural invasion, poor differentiation, and bone involvement. BWH T2b/T3 carries 50% 5-year recurrence risk.

Perineural invasion is spread of tumor cells along the connective tissue sheath of a peripheral nerve. In head-and-neck SCC it affects branches of the trigeminal and facial nerves, causing numbness, tingling, pain, or paralysis. Adjuvant radiation is typically recommended.

After low-risk SCC, full-skin examination every 6-12 months for at least 5 years. High-risk patients need every 3-6 months for 2 years, then every 6-12 months for life. Transplant recipients need every 3-6 months indefinitely. Most recurrences are caught at scheduled visits.

Cutaneous SCC in children is rare and usually signals a genetic disorder — xeroderma pigmentosum, epidermolysis bullosa, oculocutaneous albinism, or dyskeratosis congenita. Any child with cSCC warrants genetics referral and strict photoprotection from infancy.

Most insurance plans cover medically necessary SCC treatment including biopsy, excision, Mohs surgery, radiation, and approved systemic therapy. Mohs is uniformly covered for high-risk and head-and-neck lesions per NCCN criteria. Verify coverage with your insurer beforehand.